The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
|Videos|July 28, 2011
Dr. West on 4 Important Upcoming Clinical Trial Results
Author(s)H. Jack West, MD
Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.
Advertisement
H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, discusses the anticipated results of 4 lung cancer clinical trials.
- FORIS-M trial examining the single agent use of talactoferrin in previously treated patients with non-small cell lung cancer (NSCLC).
- ECOG 1505 phase III trial looking at adjuvant chemotherapy with or without bevacizumab in completely resected NSCLC.
- RADIANT trial examining adjuvant erlotinib for EGFR-positive NSCLC patients, noteworthy because of its isolation of the EGFR mutation.
- The evaluation of the recombinant MAGE-A3 vaccine platform as adjuvant therapy in MAGE-A3-Positive NSCLC in addition to or instead of standard chemotherapy.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5